CN Patent

CN115227812A — 抗pd-1抗体联合一线化疗治疗晚期nsclc的用途

Assigned to Shanghai Junshi Biosciences Co Ltd · Expires 2022-10-25 · 4y expired

What this patent protects

本发明涉及抗PD‑1抗体联合一线化疗治疗晚期非小细胞肺癌的用途。具体而言，本发明涉及抗PD‑1抗体或其抗原结合片段和一线化疗药物的组合在制备治疗非小细胞肺癌(NSCLC)药物中的用途。本发明还涉及相关的药物组合和药盒。

USPTO Abstract

本发明涉及抗PD‑1抗体联合一线化疗治疗晚期非小细胞肺癌的用途。具体而言，本发明涉及抗PD‑1抗体或其抗原结合片段和一线化疗药物的组合在制备治疗非小细胞肺癌(NSCLC)药物中的用途。本发明还涉及相关的药物组合和药盒。

Drugs covered by this patent

Patent Metadata

Patent number
CN115227812A
Jurisdiction
CN
Classification
—
Expires
2022-10-25
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Junshi Biosciences Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.